Oncology
Endometrioid Carcinoma
4
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Endometrioid Carcinoma is an early-stage landscape with 4 programs across 4 companies. The most active players are Bristol-Myers Squibb, Eli Lilly, Prism Pharmaceuticals. 2 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Analysis
Trial Status
2
clinical trials
Recruiting1 · 50%
Unknown status1 · 50%
Clinical Trials
Trial Activity
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Recruiting·—·Phase 2/3·NCT05316467·89 enrolled
Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients
Unknown status·—·Phase 2/3·NCT05565573·148 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)